Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, Meekin J 3rd, Griffin M, Bisha I, Proia TA, Miragaia RJ, Herbst R, Gupta A, Abdullah SE, Raja R, Frigault MM, Barrett JC, Dennis PA, Ascierto ML, Oberst MD.
Pore N, et al. Among authors: frigault mm.
Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6.
Cancer Discov. 2021.
PMID: 34230008